At a glance
- Originator Unknown
- Developer Bristol-Myers Squibb
- Class Cytostatic antibiotics; Glycopeptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 May 2001 No-Development-Reported for Cancer (Unknown route)